PipelineReview.com - Biotech News & Online Store - NexMed Develops Room Temperature Formulation of Alprox-TD for Erectile Dysfunction

NexMed Develops Room Temperature Formulation of Alprox-TD for Erectile Dysfunction

10 Aug 2006

NexMed Develops Room Temperature Formulation of Alprox-TD for Erectile Dysfunction

EAST WINDSOR, NJ, USA | Aug 09, 2006 | NexMed, Inc. (NASDAQ: NEXM), a developer of innovative treatments based on the

NexACT® technology, today announced that it has confirmed the long term room temperature stability of Alprox-TD®, the Company's proprietary topical treatment for erectile dysfunction ("ED").

Daniel Frank, Senior Director, Pharmaceutical Operations of NexMed, stated, "This new technical development will further enhance our product's commercialization prospects. The ease of distributing a room temperature formulation of Alprox-TD, compared to a refrigerated formulation, will be of great interest and importance to potential pharmaceutical partners with whom we are currently in discussion."

NexMed also announced today that the Company is moving forward with a new regulatory strategy for Alprox-TD which will include the filing of the New Drug Application in the U.S., and Marketing Authorization Application in Europe, during the first half of 2007.

Vivian Liu, Executive Vice President and Chief Operating Officer of NexMed, stated, "Our intent is to petition the respective U.S. and European regulatory authorities to accept the safety data we have already collected on Alprox-TD, based on our clinical database of over 3,000 patients who have already been exposed to the NexACT enhancer, in lieu of a one year open label study. We believe that our new regulatory strategy, while aggressive, has a reasonable likelihood of success."

Conference Call

NexMed's second quarter conference call previously scheduled for August 14, is now scheduled for tomorrow, Thursday, August 10th at 10:00 a.m. EDT. At that time, management will review, among other things, second quarter financial results and expected development advances of its partnered anti-fungal product in 2006. The Company intends to file its Form 10-Q for the quarter ended June 30, 2006, today August 9. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054, and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 210462 are both required for playback. The conference call will also be Webcast live at URL http://www.vcall.com/IC/CEPage.asp?ID=107664.

About NexMed, Inc.

NexMed, an innovative drug developer, offers large pharmaceutical companies the opportunity to develop new patient-friendly transdermal products, and extend patent lifespans and brand equity, through participation in early stage licensing and development partnerships. NexMed currently has a host of medicines in development, such as treatments for nail fungus, sexual disorders and more, all based on its proprietary NexACT® drug delivery technology.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability to interest potential partners in a room temperature stable formulation or petition regulatory authorities to accept safety data previously collected.

Company Contact:
Deborah Carty
NexMed, Inc.
(609) 371-8123, ext: 159
Email Contact

Investor Relations:
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
Email Contact

SOURCE: NexMed, Inc

Search in our News Channels

Search in our Online Store